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Secretion of plasminogen activator and its inhibitor by
glomerular epithelial cells
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Secretion of plasminogen activator and its inhibitor by glomerular
epithelial cells. The effects of thrombin, interleukin-l (IL-I), tumor
necrosis factor (TNF) and y.interferon (y-IFN) on the release of
plasminogen activator (PA) and inhibitor (PAl) were studied using
cultivated human glomerular epithelial cells (GECs). Species of PAs
and PAl secreted from the GECs were urokinase-type PA (u-PA) and
tissue-type PA (t-PA), while the major species was a single chain u-PA
in the amount of 28.6 2.34 ng/105 cells for 24 hours (N = 4, mean
SD), and PAl-I. The addition of increased concentrations of thrombin
(0.1 to 31.6 U/mI) into confluent cultures enhanced the GECs to release
u-PA, t-PA and PAl-i in a dose- and time-dependent manner. The
incubation of the GECs with 10 U/mI thrombin resulted in about a
fourfold increase in the concentration of u-PA, threefold in t-PA and
twofold in PAI-l. All thrombin effects, however, were suppressed by
the simultaneous addition of cycloheximide, indicating that the enhanc-
ing effects of thrombin were due to an increase in the production of PAs
and PAl-i, via protein synthesis. These thrombin effects appeared to be
dependent upon the enzymatically active site of thrombin because
DFP-thrombin had no effect. In the conditioned medium which was
under continuous thrombin stimulation for 24 hours, no u-PA activity
was detectable, even after the plasmin treatment, because a single chain
u-PA was degraded by the thrombin. The stimulation of cultured GECs
with thrombin only for the first three hours in 24 hour cultivation
showed an apparent increase in the antigenic amount of u-PA. IL-i
enhanced the release of t-PA and PAI-l, and TNF did that of u-PA and
t-PA, while y-IFN showed no significant effects. These findings indicate
that the GECs participate in the regulation of extracapillary fibrinolysis
in the glomerular microenvironment, as being modulated by thrombin
and two cytokines, IL-i and TNF.
Plasminogen activator (PA) is a highly specific serine prote-
ase that converts the proenzyme, plasminogen, into an active
proteolytic enzyme, plasmin. The two types of PAs, urokinase-
type PA (u-PA) and tissue-type PA (t-PA) can be distinguished
both physiologically and immunologically, and are present in
several tissues and cultured cells [1]. It has been demonstrated
that some cultivated cells secrete u-PA, t-PA, or both [2—4]. It
has been known that PAs play an important role in fibrinolysis,
cell migration, hormone processing and ovulation [1, 6—111.
It has been discussed that intraglomerular coagulation and
fibrinolytic processes participate in the development and pro-
gression of various renal diseases [12—19]. Glomerular damage
with fibrin deposition is occasionally followed by mesangiolysis
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and crescent formation [20, 21]. However, the relevance of
glomerular intrinsic cells in the regulation of physiological
fibrinolysis still remains almost unknown. Angles-Cano et al
[22] examined the identification and cellular localization of PAs
in human glomeruli by immunofluorescent technique and re-
ported that t-PA was located in the endothelial cells and u-PA in
the glomerular epithelial cells (GECs). They suggested that
u-PA secreted from GECs related to a pathophysiological role
of extracapillary fibrinolysis.
Thrombin is not only the key enzyme in the coagulation
system but also acts as an anti-thrombogenic agent via throm-
bomodulin and protein C-protein S system [23—26]. It also has a
direct influence upon the endothelial cells in the activation of
the fibrinolytic system [21. While cytokines such as interleukin-
1 (IL-i), tumor necrosis factor (TNF) and y-interleron (y-IFN)
also regulate the diverse functions of endothelial cells, macro-
phages and other cells, including coagulation and fibrinolytic
systems. IL-I (-a and -j3) and TNF induce procoagulant activity
due to the syntheses of tissue factor, PA inhibitor-i (PAl-i),
and suppression of protein C pathway; y-IFN causes the
increase of PA release from macrophages [6, 27, 28].
The purpose of this paper is to characterize the species of
fibrinolysis-related mediators secreted from the GECs in vitro
and to investigate the modulators affecting these fibrinolytic
functions.
Methods
u-PA of a molecular weight of 55,000 was a gift from Mochida
Pharmaceutical Co. (Tokyo, Japan). Human t-PA was purified
from the conditioned medium of a melanoma cell line (Bowes)
[29]. Latent type of human PAl- 1 was purified from a condi-
tioned medium of human fibrosarcoma cell line (HT1O8O) by a
procedure of Andreason et al [30] and FIPLC gel filtration
chromatography (TSK gel G3000SW, Toyo Soda, Tokyo, Ja-
pan). Antibodies against t-PA and u-PA were obtained from
immunized rabbits [2, 31], and antiserum against PAl-i was
taken from an immunized duck. The IgG fraction of both the
rabbits and the duck was purified using ammonium sulfate
precipitation and a column of either protein A-Sepharose or
Sepharose 4B (Pharmacia Fine Chemicals, Uppsala, Swedcn)
coupled with goat IgO against duck IgG, respectively. The
immunological specificity of each anti-IgG was examined with
immunoelectrophoretic and Western blotting techniques using
the respective crude and purified antigen samples. Anti-PA
IgGs also quenched specifically the respective enzymatic PA
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activity in a dose dependent manner, but without immunologi-
cal cross reactivity. Mouse monoclonal IgG to PA!-! or PAI-2
were from Monozyme (Lyngby, Denmark) and Biopool AB
(Umea, Sweden), respectively, and goat polyclonal IgG to
PAI-l was from Biopool AB. These monoclonal and polyclonal
anti-PAl-i IgGs, including duck anti-IgG produced by us, were
all raised by latent type of PAl-I and showed much less binding
activity to PAI-lt-PA or u-PA complex than that to free PA!-!
with Western blotting analyses. Monospecific IgG against
u-PA, t-PA or PAI-l was prepared by passing rabbit and duck
anti-IgGs through a column of Sepharose 4B coupled with
purified u-PA, t-PA or PAl-i. The absorbed IgG was eluted with
0.1 M glycine-HCI, pH 2.5. Fifty microliters of 1.0 M Tris-HC1,
pH 9.0 was added to each eluate (1 ml). The IgG fractions,
dialyzed against 0.01 M carbonate buffer, pH 9.5, were conju-
gated with horseradish peroxidase (HRP) by the periodate
method [32]. Bovine alpha-thrombin was purified by cationic
ion exchange chromatography from commercially available
thrombin (Mochida Pharm. Co., Tokyo, Japan). The final
preparation had a specific activity of 3600 U/mg of protein.
Diisopropylfluorophosphate (DFP) treated thrombin was pre-
pared by reacting thrombin with 10 mri DFP at pH 7.2 for one
hour at 37°C, and then dialyzed against 0.01 M phosphate
buffered saline, pH 7.4 (PBS). The plasminogen was prepared
from human plasma by the affinity column chromatography of
lysine-Sepharose (Pharmacia) [33]. HRP, DFP, hirudin, human
plasmin, bovine serum albumin and cycloheximide were ob-
tained from Sigma Chemical Co. (St. Louis, Missouri, USA),
aprotinin from Bayer Co. (Leverkusen, FRG), and IL-l (hu-
man, cell-line derived IL-l) from Genzyme Inc. (Boston, Mas-
sachusetts, USA). Single chain u-PA and TNF were from
Mochida Pharmaceutical Co. (Tokyo, Japan) and y-!FN was
from Takeda Pharmaceutical Co. (Tokyo, Japan).
Isolation of glomerular epithelial cells
Fresh human adult kidneys were obtained at the nephrec-
tomy for the localized tumors. The tissue samples were proc-
essed under sterile conditions by a modification of the method
of Striker, Killen and Farm [34]. Briefly, the cortical segments
were minced in Waymouth's medium (GIBCO Laboratories,
Grand Island, New York, USA) containing 100 U/mI of peni-
cillin and 100 pg/ml streptomycin. Then the segments were
pushed through a 60-mesh stainless steel screen with a pestle
and rinsed by Waymouth's medium. The filtrate was poured
through a 100-mesh stainless steel screen. Remaining glomeruli
on the 100-mesh screen were separated from tubular fragments
by sufficient repeated passages over a 100-mesh screen. The
final preparation was more than 98% free from fragments of
both tubular tissues and Bowman's capsules by estimating with
phase contrast microscope (Olympus, Tokyo, Japan).
Isolated glomeruli were incubated with clostridium collage-
nase (CLSPA, 750 U/ml, Cooper Biomedical Co., Freehold,
New Jersey, USA) and passed over a 325-mesh stainless steel
screen. After centrifugation of the filtrate, the sediment was
resuspended with Waymouth's medium containing 20% fetal
calf serum (GIBCO Labs) and epidermal growth factor (EGF,
10 ng/ml, Collaborative Research Inc., Lexington, Massachu-
setts, USA), and implanted in culture dishes coated with
fibronectin (5 g/ml, Collaborative Research), and incubated in
an atmosphere of humidified air containing 5% CO2. After about
one week, colonies of GECs were subcloned using 0.1% trypsin
and 0.02% EDTA in stainless steel cylinders. Third passaged
cells were used in all experiments.
Identification of GECs
Epithelial morphologies of isolated cells were examined by
phase contrast microscopy, scanning electron microscopy
(SEM), transmission electron microscopy (TEM) and immuno-
histochemical methods. The cells grown on coverslips were
prepared for SEM by fixation with 3% glutaraldehyde in 0.1 M
cacodylate buffer (pH 7.4), postfixed in 1% osmium tetroxide,
dehydrated in alcohol series, immersed in isoamyl acetate, and
critical-point dried with carbon dioxide (HCP-2, Hitachi, To-
kyo, Japan). After sputter-coating with platinum palladium, the
cells were examined with a SEM (JSM-35CF, JEOL, Tokyo,
Japan). For TEM, cells grown on glass slides were fixed the
same as for SEM, dehydrated in alcohol series, and embedded
in Epon 812. Some embedded samples were vertically re-
embedded in Epon 812. Ultrathin sections were stained with
uranyl acetate and lead citrate, and examined with a TEM (1200
EX, JEOL). These cells were studied immunohistochemically
using PHM-5 (mouse monoclonal anti-human GEC IgG, Aus-
tralian Monoclonal Development Pty., Artarmon, Australia),
which reacted with surface polyanion of GECs after periodate-
lysine-paraformaldehyde fixation at 4°C for 15 minutes [35], and
rabbit anti-human von Wiliberand factor IgG (Dakopatts A/S,
Glostrup, Denmark) and rabbit anti-human myosin IgG (Immu-
notech S.A., Marseille, France) after aceton fixation at 4°C for
five minutes. The immunostaining procedures were carried out
using a Vectastain ABC kit (Vector Laboratories, Inc., Burlin-
game, Vermont, USA) and the peroxidase reaction was devel-
oped with diaminobenzidine. Indirect immunofluorescent study
for cytokeratin antigens, using mouse monoclonal anti-human
cytokeratin IgG (Becton Dickinson Immunocytometry Sys-
tems, Mountain View, California, USA) against cytokeratins
with Moll's catalog numbers 8, 18, and 19 [36], and FITC-rabbit
anti-mouse IgG (Miles Scientific, Naperville, Illinois, USA),
was performed after methanol fixation at —20°C for five minutes
and then aceton at —20°C for five minutes. All specimens were
observed with an epifluorescent microscope (Olympus, Tokyo,
Japan). To test for fibroblast contamination, the cells were
cultured in Eagle's minimum essential medium containing D-
valine instead of L-valine (GIBCO Labs) and 20% dialyzed fetal
calf serum with D-valine medium [37].
Stimulation of GECs
GECs grown to confluency were washed with PBS for 10
minutes two or three times, and incubated with both serum- and
EGF-free Waymouth's medium (600 p1/dish) added with throm-
bin (0.316 to 31.6 U/ml), IL-i (1 to 10 U/ml), TNF (1.6 to 1,000
U/ml) or y-IFN (1 to 1,000 U/mi). Stimulating media containing
thrombin and cytokines were, moreover, added with polymyxin
B sulfate (5 g/ml, Sigma Chemical Co.) to inhibit the effect of
endotoxin. The conditioned media were harvested after 24
hours of incubation and centrifuged at 10,000 rpm for five
minutes. The supernatants were stored at —70°C.
To examine the effect of early and transient exposure to
thrombin on the release of u-PA from the GECs, the GECs were
incubated with thrombin (3.16 U/ml) for only the first three
hours during 24-hour cultivation. In the thrombin-free control,
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the medium was exchanged in the same manner to a new serum
free medium at three hours, as in the case of the thrombin-
stimulated GECs. The supernatants were harvested at 4, 6, 12
and 24 hours, centrifuged and stored at —70°C.
Effects of DFP-thrombin and cycloheximide
DFP-thrombin (0.033 to 10.5 g/m1), DFP-thrombin (1.05
g/m1) with thrombin (1.0 U/mi) and cycioheximide (10 to 1,000
nM) with thrombin (3.16 U/mI) were also applied to the GECs in
the same manner as described above.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and
fibrin autography
According to Laemmii [38], SDS polyacrylamide slab gels
were prepared using a separating gel of 10% acrylamide (Naka-
rai Chemicals, Kyoto, Japan) and a stacking gel of 4% acryl-
amide. The electrophoretic mobility of the samples was esti-
mated by comparing with those of high and low molecular
weight standards (BlO-RAD Laboratory, Richmond, Virginia,
USA). Fibrin autography was performed according to Levin
and Loskutoff [31. To determine the immunological nature of
the PAs, 7 jg/m1 of rabbit anti-u-PA IgG or anti-t-PA IgG was
added to the fibrin agarose gel.
Immunoblotting assay for u-PA, t-PA and PAl-I antigens
The conditioned media obtained from the cultures with or
without thrombin stimulation were harvested after 24 hours and
concentrated by using 2% deoxycholic acid and 24% trichloro-
acetic acid. SDS-PAGE of the concentrated media with or
without reduction by 2% mercaptoethanol, and an electropho-
retic transfer of the protein to a nitrocellulose sheet were
performed according to the method of Towbin, Staehelin and
Gordon [39J. The blot was reacted with rabbit anti-u-PA or t-PA
IgG, or goat anti-PAl-i IgG (1 g/ml). Immunoreactive proteins
were stained by the Vectastain ABC kit. The peroxidase was
developed with 4-chioro- l-naphthol.
Enzyme-linked immunosorbent assay (ELISA) for u-PA, t-PA
and PAl-I antigens
The assay system used was a modification of that of Bergs-
dorf, Nilsson and Wallén [40]. In brief, rabbit anti-u-PA or t-PA
IgG, or mouse monoclonal anti-PAl-I lgG (100 ui, 5 g/m1) in
0.1 M NaHCO3 was placed on a 96-well microtiter plate (Coster,
Cambridge, Massachusetts, USA) and kept overnight at 4°C.
After washing and blocking with 1% bovine serum albumin,
several diluted samples or antigen standards of u-PA, t-PA and
PAl-i were added to each well and kept at 4°C overnight.
HRP-conjugated monospecific rabbit IgG (100 p1) against u-PA
(0.1 g/ml) or t-PA (0.5 pg/mI), and duck anti-PAl-i IgG (1
jsg/ml) were put into each well and incubated for three hours at
room temperature. Then, after washing the plates, 0.1 M citrate
phosphate buffer, pH 5.0, (100 jsl) containing 0.4 mg/mI o-
phenylenediamine and 0.01% H202 was added and incubated
for about two hours in a dark and wet chamber at 37°C. The
absorbance was measured at 405 nm using a multiscan spectro-
photometer (Corona Co.). All samples were examined in dupli-
cate. Standard curves of u-PA, t-PA and PAl-i were reproduc-
ible and linear in a dose-dependent manner in the range of 0.1 to
10 ng/ml, 0.03 to 1.0 ng/ml, and 0.7 to 25 ng/ml, respectively.
Fibrinolytic activity of u-PA using chromogenic assay
According to the modified method of Lijnen et a! [41],
amidolytic activities of u-PA in samples with or without the
plasmin treatment were measured with an S-2444 (3 mi,
Kabivitrum, Stockholm, Sweden) in 0.05 M Tris-HC1, pH 8.8,
containing 0.1 M NaCl, 0.01% Triton X-100 and 0.01% NaN3.
Rabbit anti-t-PA IgG (500-fold amount of 50% inhibitory IgG
concentration, which was 0.24 g/ml for 500 mIU/ml t-PA
activity) was added to selectively measure the u-PA activity in
the samples. Hirudin (20 U/mi) was also added to inhibit the
direct hydrolytic effect of thrombin on S-2444, as well as
aprotinin (100 KIU/mI), to inhibit the residual plasmin activity.
After incubation with S-2444 at 37°C for several hours, the
absorbance at 405 nm was measured using a multiscan spectro-
photometer (Corona Co.). Fibrinolytic activity of t-PA was
measured according to the method of Wiman, Mellbring and
Rânby [42] using S-2251 (0.3 mi, Kabivitrum, Stockholm,
Sweden), 0.1 mg/mi plasminogen, 70 g/ml soluble fibrin and 20
U/mi hirudin, and rabbit anti-u-PA IgG (500-fold amount of 50%
inhibitory IgG concentration, which was 0.3 g/m1 for 1 lU/mi
u-PA activity) was added to suppress u-PA activity in culture
media.
To examine the direct effect of thrombin on single chain
u-PA, single chain u-PA (200 g/ml) was incubated with throm-
bin (0.1 to 10 U/ml) in PBS containing 0.02% Tween 80, for 5 to
60 minutes at 37°C, and then u-PA activity after plasmin
treatment was spectrophotometrically measured with S-2444 as
described above.
Results
Culture of GECs
We used three passaged GECs for all experiments, because
the GECs which were passaged more than four times were
prone to show degenerative changes such as intracytoplasmic
vacuoles and cellular shrinkage. We used dishes coated with
fibronectin for the first and second passages to increase the
plating efficiency. Fibronectin coating, however, was not nec-
essary at the third passage of the GECs, because both good
plating efficiency and cell growth were well maintained by
seeding a full number of GECs. The third passaged GECs
showed a confluent monolayer growth exhibiting a cobblestone
appearance (Fig. la). Immunohistochemically, their cytoplasm
was stained in a granular pattern with PHM 5 (Fig. ib). By
indirect immunofluorescent technique using mouse monocional
anti-cytokeratin IgG, a large amount of reactive products was
demonstrated in the cytoplasm of these cells (Fig. ic). Upon
examining with SEM, abundant microvilli were found on the
surface of these cells (Fig. id). By TEM, tight junctions were
observed. Neither peripheral dense bodies nor Weidel-Palade
bodies were seen in their cytoplasm. These cells could not be
stained immunohistochemically with either anti-von Willberand
factor antibody or anti-myosin antibody. These findings were
almost the same as those reported previously [43]. Cell growth
activity was easily maintained in a medium containing D-valine
substituted for L-valine, indicating that these cells were not
fibroblasts. The contamination of endothelial cells, mesangial
cells and fibroblasts was very improbable.
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Fig. 1. a. Cultured GECs at the third passage. GECs show a cobblestone appearance. b. Immunohistochemical staining of GECs with PHM-5
antibody. c. Indirect immunofluorescence of GECs with mouse anti-human cytokeratin IgG. d. SEM of GECs. Many microvilli are present.
Characterization of PAs in conditioned medium of GECs
Fibrin autography revealed that GECs released PAs with
molecular wts of 120,000 and 54,000 into the conditioned
medium. The fibrinolytic activity of the band with a molecular
wt of 120,000 was quenched by anti-t-PA IgG, and that with a
molecular wt of 54,000 by anti-u-PA IgG (Fig. 2). Then, we
assessed the effect of piasmin on the PA activities in the
conditioned medium by fibrin autography and amidolytic activ-
ity. The fibrinolytic activity with a molecular wt of 54,000 was
markedly enhanced after the piasmin treatment (Fig. 2), and
this fibrinolytic activity was completely quenched by anti-u-PA
IgG. The results of their amidolytic activities measured with
S-2444 were similar to the enhancement of u-PA activity
observed in fibrin autographies. Namely, the u-PA activity after
the plasmin treatment was enhanced by about 100-fold, from
0.023 0.001 to 2.54 0.19 IU/105 cells. Immunoblotting
analyses of the non-plasmin-treated conditioned medium under
the presence of 2% mercaptoethanol, using anti-u-PA IgG,
revealed a single band of a molecular wt of 54,000. However,
the immunoblots of the conditioned media incubated with
plasmin (0.001 CU/mI) at 37°C for one hour and reduced with
2% mercaptoethanol revealed a separation to two subunits of
molecular wts of 33,000 and 21,000 (Fig. 3). These findings
indicated that the majority of u-PA in the conditioned media
was identical to single chain u-PA. Immunoblotting for t-PA
revealed a single band with a molecular wt of 120,000. On the
other hand, PAl-i had a molecular wt of 50,000. After thrombin
treatment, the PAl-I related band changed to two bands with
molecular wts of 50,000 and 47,000 (Fig. 3). PAI-2 related
antigen was not detectable. In the conditioned media without
any stimulant, the amount of u-PA antigen released from the
GECs during 24 hour cultivation was about 28.6 2.34 ng/l05
cells; t-PA was about 0.58 0.14 ng/105 cells, and the ratio of
antigens between the released u-PA and t-PA was about 50.
Effect of thrombin on release of u-PA, t-PA and PAl-i
from GECs
The addition of increased concentrations of thrombin to the
GEC cultures in serum free medium resulted in the increases in
the levels of u-PA, t-PA and PAI-l antigens in the conditioned
medium in a dose dependent manner (Fig. 4). At a thrombin
concentration of 3.16 U/mI, the levels of u-PA antigen almost
reached a plateau. The incubation of GECs with 10 U/mi
thrombin resulted in about a fourfold increase in the u-PA
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Fig. 2. Fibrin autography of the conditioned medium of GECs after
SDS-PAGE. After 24-hr cultivation of GECs in the serum free medium,
conditioned media were harvested. The conditioned medium contained
PA activities with molecular wt of 120,000 and 54,000 (lane I and 4).
The fibrinolytic activity with a molecular wt of 120,000 was quenched
by anti-t-PA IgG (lane 2), and that with a molecular wt of 54,000 by
anti-u-PA IgG (lane 3). The fibrinolytic activity of band with a molecular
wt of 54,000 was markedly enhanced by plasmin treatment (0.001
CU/ml) for one hour at 37°C (lane 5) compared with that without
plasmin treatment (lane 4). Lanes 1, 2 and 3 were incubated for 16 hr,
and lane 4 and 5 for 6 hr at 37°C.
150
Fig. 3. Western immunoblotting analyses for u-PA, t-PA and PAl-i of
conditioned medium. After 24-hr cultivation in the serum free medium,
conditioned media of the GECs were harvested. Lanes 1, 2 show
immunoblots for u-PA, lane 3 for t-PA, lanes 4 and 5 for PAl-I. The lane
2 was treated with plasmin (0.001 CU/mI) for 1 hr at 37°C and reduced
with 2% mez-captoethanol. The conditioned medium of the lane 5 was
harvested after 24-hr cultivation under the thrombin stimulation (1.0
U/mi).
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Fig. 4. Effects of increased concentrations of thrombin and DFP-thrombin on u-PA, t-PA or PAl-i antigen released from GECs. Conditioned
media were harvested after 24-hr cultivation. Thrombin stimulation showed a dose-dependent increase in antigenic levels of u-PA, t-PA and PAl- 1.
Symbols are: thrombin (I•A), DFP-thrombin (OUA). Abbreviation is DFP, diisopropylfluorophosphate. N = 4; values are means SD.
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concentration, threefold in t-PA and twofold in PAT-i. DFP- thrombin and thrombin was almost the same as that under the
thrombin did not stimulate GECs to increase the release of the stimulation of thrombin only (Table 1). The time courses of
u-PA, t-PA and PAt-i (Fig. 4). The level of u-PA, t-PA or PAl-i u-PA, t-PA and PAT-i antigens released from GECs are shown
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Fig. 5. Time course of u-PA or t-PA or PAl-i antigens released from GECs under thrombin stimulation (3.16 U/mi). The releases of u-PA, t-PA
and PAl-I showed a time-dependent increase. Symbols are: thrombin (•UA), control (ODL). N = 4; values are means SD.
q.)
or
2
Thrombin, U/mi
Fig. 6. Effects of increasing concentrations of thrombin on u-PA
activity in conditioned media. Conditioned media were harvested after
24-hr cultivation under the thrombin stimulation and measured with (•)
orwithout (0) plasmin (0.001 CU/mI) treatment for 1 hr at 37°C (N = 4,
mean SD).
Table 1. Effects of DFP-thrombin on u-PA, t-PA and PAI-l releases
from cultured human glomerular epithelial cells
Treatment
u-PA t-PA PAl-I
ng/10'cells
None 29.5 2.8 0.60 0.06 18.7 2.5
Thrombin 1.0 U/mI 114.5 3.4° 1.63 0.10° 30.6 1.9°
DFP-thrombin 1.05 jsg/ml 28.9 2.7 0.60 0.04 19.9 3.8
DFP-thrombin 1.05 pg/ml
+ thrombin 1.0 U/mi 110.3 8.9a 1.69 o.lIa 32.8 4.3°
N = 4, values are means SD. Values were measured after 24-hour
cultivation.
P < 0.01 as compared to control values.
in a time dependent manner. In particular the u-PA release was
parabolically increased after six hours, and the t-PA and PAl-i
after 12 hours.
In a continuous stimulation of GECs with thrombin, the u-PA
activity in the conditioned medium after plasmin treatment was
dramatically decreased (Fig. 6). The conditioned media, which
was under thrombin stimulation for only the first three hours in
24 hour cultivation, showed an increase of u-PA antigen in a
time dependent manner. But, these u-PA antigen levels were
less than the continuously stimulated one with thrombin at
respective incubation times. The u-PA activity after 24 hours
was 4.8 0.08 IU/ml only after plasmin treatment. However,
no significant difference could be found between its activity
level and the level for the control (Table 2).
Effect of cycloheximide
To examine whether thrombin enhanced the release of u-PA,
t-PA and PAT-i via the intracellular protein synthesis, cyclo-
heximide (10 to 1,000 nM) was simultaneously added to the
medium. Although the concentration of 10 flM had no effect,
higher concentrations suppressed the levels of u-PA, t-PA and
PA!-! releases (Fig. 7). These findings revealed that thrombin
0,
'a
'a
a
a
=
3
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Table 2. u-PA antigen and activity under thrombin stimulation for
only first three hour during 24 hour cultivation and continuous
thrombin stimulation for 24 hours 100
•
u-PA antigen
ng/mi
u-PA activity IU/ml
Plasmin
non-treated treated
Control 38.9 0,5 ND 4.6 0.2
Thrombin 3.16 U/mi
Only first 3 hr 68.0 3.Oa ND 4.8 0.1
Continuous 24 hr 180.1 14.0" ND ND
GECs were stimulated with 3.16 U/mI of thrombin. All values were
measured after 24-hour cultivation. Abbreviation is ND, not detectable
(below 0.1 lU/mi). N = 3, values are presented as means SD.
a P < 0.01 as compared to control value
b P < 0.01 as compared to thrombin stimulated value for only first
Cycloheximide, w
enhanced the synthesis of u-PA, t-PA and PA!-! antigens in
GECs.
Effects of IL-I, TNF and -y-IFN on releases of PAs and
PM-i from GECs
IL-i stimulation (10 U/mi) resulted in more than a twofold
increase in the t-PA concentrations in the medium, and about a
1.5-fold increase in PAl-i. On the other hand, IL-i stimulation
had no effect on u-PA release from GECs (Fig. 8A). TNF
stimulation (200 U/mi), equivalent to 5.2 >< 10_12 M, revealed
1.5 to twofold increases in u-PA and t-PA releases, and almost
no effect on PAl-i release. However, levels of them at 1,000
U/mi of TNF stimulation were conversely suppressed as com-
pared with those at 200 U/mi of TNF, probably, suggesting the
cytotoxicity of TNF because the shape of GECs changed to be
spindle (Fig. 8B). -IFN had no stimulant effect on the releases
of PAs and PAl-i from GECs (Fig. 8C).
A change of u-PA activity under the stimulations of IL-i,
TNF or 'y-IFN after plasmin treatment was similar to that of
u-PA antigen level, but no t-PA activities could be detected in
them.
Direct effect of throinbin on single chain u-PA
As there was a discrepancy between the release of u-PA
antigen and u-PA activity in the conditioned media treated with
thrombin, the direct effect of thrombin on single chain u-PA was
examined. When the purified single chain u-PA was incubated
with thrombin, thrombin rapidly decreased the generation of
u-PA activity in time and dose dependent manners (Fig. 9). But
two chain u-PA activity was unaffected by the incubation of
thrombin.
Discussion
In this paper, we demonstrated that cultured human GECs
secreted u-PA, t-PA and PAT-i, and these syntheses and
releases were modulated by thrombin, IL-i and TNF, but not
by y-IFN.
The scavenger mechanism of extracapillary fibrin deposits in
glomeruli is controversial in various glomerular diseases. The
infiltrating macrophages and/or mesangial cells are considered
to play a main role in the removal of fibrin deposits [44]. The
fibrinolytic function of GECs has been also suggested to con-
Fig. 7. Effect of cycloheximide on the release of thrombin-induced
u-PA, t-PA and PAl-i antigens. Simultaneous addition of cyclohexi-
mide decreased the release of u-PA (•), t-PA (U) or PAl-i (A) antigen
from GECs under the 24-hr stimulation of thrombin (3.16 U/mi) in a
dose-dependent manner (N = 3, mean SD).
tribute to the extracapillary fibrinolysis in glomeruli by Angres-
Cano et al from the immunohistochemical findings [22]. In the
present study, PAs and PAT released from the GECs were
characterized by quenching experiments and Western immuno-
blotting methods. u-PA was predominant in the PA species
released by GECs. Particularly, most of the u-PA in the
conditioned medium was a latent form of u-PA, namely single
chain u-PA. This is compatible with the previous findings that
single chain u-PA is the predominant extracellular form of PAs
[7]. The secretion of u-PA by these GECs in serum-free
conditioned media for 24 hours was about 29 ng/105 cells/0.3 ml
and was much higher (approximately 14 times) than that by
human foreskin microvascular endothelial cells [45], although
there were some differences in culture conditions such as
supplementation of 0.03% bovine serum albumin and passage
numbers. On the other hand, t-PA existed mainly in the form
with a molecular wt of 120,000, indicating t-PAPAI complex as
being judged from previous reports [2, 3].
Although epithelial cells of urinary tubules and transitional
epithelial cells may represent a major source of u-PA in the
urinary tract [1], we clearly demonstrated that cultivated GECs
also synthesized and released single chain u-PA. The patho-
physiological role of u-PA in the kidney still remains unclear. A
part of the synthesized single chain u-PA binds to the cell-
surface receptor for u-PA as cell-associated u-PA, other of them
presents in the extraceliular spaces either in a free form or
complexed with PAl [46]. On the cell surface, plasminogen was
converted to plasmin by the receptor-binding u-PA. This plas-
mm may not only play a fibrinolysis but also cleave directly the
extracellular matrix including the basement membrane, and
indirectly collagens due to the conversion of a pro-collagenase
to active collagenase. Therefore, u-PA released from GECs
may participate not only in extracapiliary fibrinolysis but also in
the regulation of matricial degradation in the glomeruli.
Endothelial cells from various sources were investigated
minutely regarding the release of PAs in vitro. Many investiga-
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tors reported that thrombin enhanced the secretion of PAs
and/or PAT-i from endothelial cells [45, 47, 481. Nakashima,
Sueishi and Tanaka also reported that thrombin stimulated
cultured bovine venous endothelial cells to produce and release
t-PA and PAl- 1 in a conditioned media through its direct action
on endothelial cells [2]. In the present study, we demonstrated
that thrombin enhanced the release of u-PA, t-PA and PAl-i
antigens from the GECs into the serum free conditioned media,
in dose- and time-dependent manners, and these effects were
suppressed by the addition of cycloheximide. These findings
I
10
0 1 10
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Fig. 8. Effect of IL-I (A), TNF (B) or y-IFN (C) on releases of u-PA,
I-PA and PAl-I antigens from GECs. IL-I stimulation (10 U/mI)
showed a significant increase in the t-PA and PAI-l concentrations;
however, it had no effect in u-PA. TNF stimulation (200 U/mI)
__________________
showed 1.5- to 2-fold increase in u-PA and t-PA concentrations andI 1 almost no effect in PAl-I. y-IFN showed no significant effect on the
100 1000 PAs and PAl-I releases. Symbols are: u-PA (•), t-PA (U), PAI-l
(A), * P < 0.01, ** P < 0.05. N = 3; values are means SD.
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Fig. 9. Inactivation of single chain u-PA with thrombin. The activity of
single chain u-PA (200 ng/ml) with thrombin treatment was rapidly
decreased in time- and dose-dependent manners. A level of initial
activity was expressed as 100%. u-PA activity was assayed with S-2444
as described in Methods. Symbols are: thrombin at 0 (S), 0.1(0), 1.0
(D), and 10 () U/mi.
indicate that the enhancing effects of thrombin are mainly due
to an increase in the production of u-PA, t-PA and PAl- 1, via
protein synthesis. Enzymatically inactivated thrombin with
DFP did not increase PAs and PAl-i levels in the conditioned
medium, indicating that the enzymatically active site of throm-
bin was necessary to enhance the release of PAs and PA!-!
from GECs.
Loskutoff reported that u-PA activity in the conditioned
medium decreased dramatically after the addition of thrombin
in bovine aortic endothelial cells in vitro [47]. Thrombin has
been shown to proteolytically cleave at Arg156-Phe 157 of single
chain u-PA to induce the inactive two chain u-PA [49, 50]. On
the other hand, PAl-i is also cleaved by thrombin, resulting in
its conversion into inactive PA!-! products [45, 51]. In our
studies of the continuous stimulation of GECs with thrombin,
u-PA activity could not be detected even after the plasmin
treatment and the immunoblotting analyses for u-PA under the
reducing condition revealed the two subunits of u-PA. These
findings indicated that thrombin inactivated single chain u-PA
and lost the ability of single chain u-PA to be converted into the
active two chain u-PA. While, thrombin induces a release of PA
from the vascular bed within a few minutes [52], and is rapidly
inactivated mainly by binding with anti-thrombin III in plasma
or on the endothelial surface [53]. Thrombin activity, however,
is retained for many hours in the culture medium. Therefore, to
investigate the enhancement of PA synthesis by thrombin from
GECs, we performed the stimulation of GECs with thrombin
for only the first three hours of a 24-hour cultivation instead of
continuous stimulation for 24 hours. The level of u-PA antigen
significantly increased alter thrombin stimulation for the first
three hours. This phenomenon indicated that the enhancing
effect of thrombin on u-PA synthesis was present continuously
after the removal of thrombin. On the other hand, the level of
u-PA activity did not show a significant increase as compared
with control one. The reason of this discrepancy between u-PA
antigen and activity could not be resolved. Considering that our
data obtained were analyzed in the fluid and fibrin-free condi-
tion, it is necessary to clarify the binding sites of thrombin and
the modulation of fibrinolytic activity on a solid-phase such as
fibrin or membrane surface of GECs.
Recent studies document that inflammatory cytokines are
potent modulators of a variety of cell functions [27, 28, 54].
Infiltration of macrophages and lymphocytes has been shown
glomeruionephntic diseases. The production of IL-i and TNF
by macrophages infiltrating in glomeruli was also reported to be
stimulated by the deposition of immune complexes [55] and
IL-i is potent stimulant for the proliferation of mesangial and
endothelial cells [56] and for renal prostaglandin synthesis [57].
Moreover, intrinsic cells such as mesangial and endothelial cells
have also been shown to release IL-! [58, 59]. As described
above, IL-! and TNF released from these cells have been
suggested to offer various effects on glomerular intrinsic cells.
Investigating the effects of IL-i, TNF and y-IFN on PAs and
PAT-i releases from GECs, IL-i and TNF have a stimulating
effect upon PAs and PA!-! releases from GECs, but 'y-!FN does
not, indicating that IL-! and TNF produced in glomeruli may
modulate the fibrinolytic function of the GECs. y-IFN, how-
ever, may participate in a potentiation of other cytokines
effects.
In conclusion, the facts that GECs secrete u-PA, t-PA and
PA!-!, and thrombin, IL-! and TNF modulate the fibnnolytic
activity of GECs strengthen the hypotheses that GECs would
participate in the regulation of extracapillary fibrinolysis in
g!omeruli and local inflammatory and immune processes could
affect the fibrinolytic activity of GECs.
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